218 related articles for article (PubMed ID: 2064959)
1. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
2. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
4. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
von Wussow P; Pralle H; Hochkeppel HK; Jakschies D; Sonnen S; Schmidt H; Müller-Rosenau D; Franke M; Haferlach T; Zwingers T
Blood; 1991 Jul; 78(1):38-43. PubMed ID: 2070058
[TBL] [Abstract][Full Text] [Related]
5. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
7. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
Geissler D; Gastl G; Aulitzky W; Tilg H; Gaggl S; Konwalinka G; Huber C
Leuk Res; 1990; 14(7):629-36. PubMed ID: 2388474
[TBL] [Abstract][Full Text] [Related]
10. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
11. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
Nolte KU; Günther G; von Wussow P
Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
[TBL] [Abstract][Full Text] [Related]
12. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
Bergsagel DE; Messner H
Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
15. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
16. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
Von Wussow P; Hehlmann R; Hochhaus T; Jakschies D; Nolte KU; Prümmer O; Ansari H; Hasford J; Heimpel H; Deicher H
J Interferon Res; 1994 Aug; 14(4):217-9. PubMed ID: 7822880
[No Abstract] [Full Text] [Related]
17. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype.
Krasagakis K; Garbe C; Krüger S; Orfanos CE
J Invest Dermatol; 1991 Aug; 97(2):364-72. PubMed ID: 1712824
[TBL] [Abstract][Full Text] [Related]
18. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint.
Dowding C; Guo AP; Maisin D; Gordon MY; Goldman JM
Br J Haematol; 1991 Feb; 77(2):165-71. PubMed ID: 2004017
[TBL] [Abstract][Full Text] [Related]
19. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
Aulitzky WE; Peschel C; Desprès D; Aman J; Trautman P; Tilg H; Rudolf G; Hüttmann H; Obermeier J; Herold M
Ann Hematol; 1993 Nov; 67(5):205-11. PubMed ID: 7694661
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
